Evofem Biosciences Cash on Hand 2013-2022 | EVFM
Evofem Biosciences cash on hand from 2013 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Evofem Biosciences Annual Cash on Hand (Millions of US $) |
2021 |
$13 |
2020 |
$71 |
2019 |
$24 |
2018 |
$2 |
2017 |
$2 |
2016 |
$11 |
2015 |
$38 |
2014 |
$76 |
2013 |
$4 |
2012 |
$11 |
Evofem Biosciences Quarterly Cash on Hand (Millions of US $) |
2022-03-31 |
$7 |
2021-12-31 |
$13 |
2021-09-30 |
$24 |
2021-06-30 |
$62 |
2021-03-31 |
$64 |
2020-12-31 |
$71 |
2020-09-30 |
$87 |
2020-06-30 |
$124 |
2020-03-31 |
$11 |
2019-12-31 |
$24 |
2019-09-30 |
$36 |
2019-06-30 |
$51 |
2019-03-31 |
$1 |
2018-12-31 |
$2 |
2018-09-30 |
$13 |
2018-06-30 |
$23 |
2018-03-31 |
$6 |
2017-12-31 |
$2 |
2017-09-30 |
$6 |
2017-06-30 |
$8 |
2017-03-31 |
$10 |
2016-12-31 |
$11 |
2016-09-30 |
$14 |
2016-06-30 |
$21 |
2016-03-31 |
$24 |
2015-12-31 |
$38 |
2015-09-30 |
$51 |
2015-06-30 |
$63 |
2015-03-31 |
$71 |
2014-12-31 |
$76 |
2014-09-30 |
|
2014-06-30 |
|
2014-03-31 |
|
2013-12-31 |
$4 |
2012-12-31 |
$11 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.005B |
$0.008B |
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
|